Back
Top 1.0%
17.6%
Top 39%
17.6%
Top 1%
8.9%
Top 46%
5.9%
Top 19%
5.9%
Top 1%
5.9%
Top 0.8%
5.0%
Top 8%
5.0%
Top 1%
3.8%
Top 3%
1.9%
Top 3%
1.9%
Top 1.0%
1.5%
Top 2%
1.5%
Top 17%
1.3%
Top 60%
1.2%
Top 0.5%
1.0%
Top 5%
0.9%
Top 9%
0.7%
Top 20%
0.7%
Top 2%
0.7%
Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2- breast cancer
2026-02-09
oncology
Title + abstract only
View on medRxiv
Show abstract
Recurrence scores based on a 21-gene assay are clinically useful for predicting prognosis and chemotherapy benefit in postmenopausal node-positive breast cancer patients, but its performance in premenopausal patients is inconsistent. Here, we evaluated Ataraxis Breast RISK (ATX), an AI test that predicts recurrence risk, and compared it with the genomic assay. ATX identified high risk patients misclassified as low risk by the genomic assay and therefore may refine selection of patients for adjuv...
Predicted journal destinations
1
Cancers
57 training papers
2
PLOS ONE
1737 training papers
3
Frontiers in Oncology
34 training papers
4
Scientific Reports
701 training papers
5
Nature Communications
483 training papers
6
Clinical Cancer Research
22 training papers
7
British Journal of Cancer
22 training papers
8
eLife
262 training papers
9
Cancer Medicine
17 training papers
10
BMC Cancer
21 training papers
11
iScience
74 training papers
12
Communications Biology
36 training papers
13
International Journal of Molecular Sciences
39 training papers
14
JAMA Network Open
125 training papers
15
BMJ Open
553 training papers
16
Archives of Clinical and Biomedical Research
18 training papers
17
Diagnostics
36 training papers
18
PeerJ
46 training papers
19
Proceedings of the National Academy of Sciences
100 training papers
20
International Journal of Cancer
18 training papers